截至2025年9月30日收盘，有棵树(300209)报收于6.62元，下跌4.47%，换手率18.65%，成交量91.37万 手，成交额5.91亿元。 当日关注点 交易信息汇总资金流向 9月30日主力资金净流出1394.8万元，占总成交额2.36%；游资资金净流出2063.78万元，占总成交额 3.49%；散户资金净流入3458.58万元，占总成交额5.85%。 违规处罚提醒监管公告 9月29日有棵树公开信息显示，有棵树股东深圳市天行云供应链有限公司，董事长肖四清、王维因未及 时披露公司重大事件，涉嫌违反证券法律法规被中国证券监督管理委员会立案调查。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：9月30日主力资金净流出1394.8万元，占总成交额2.36%。 来自违规处罚提醒：9月29日有棵树股东及高管因未及时披露重大事件被证监会立案调查。 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

来源：格隆汇 温馨提示：财经最新动态随时看，请关注金投网APP。 | | | 9月30日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 | 主要内容 | | | 森廟传感 | 实际控制人之一致行动人拟减持不超过1.09%股份 | | | 尔康制药 | 控股股东拟减持不超过2.04%股份 | | | 安德利 | BVI东华拟减持不超1.00%股份 | | | 智洋创新 | 控股股东及其一致行动人拟减持合计不超过422.5万股 | | | 振江股份 | 胡震拟减持不超3%股份 | | | 四川黄金 | 北京金阳拟减持不超过1.8%股份 | | 股东减持 | 燕麦科技 | 实际控制人、控股股东刘燕合计减持1. 2897%公司股份 | | | 国机重装 | 中行德阳分行、中行镇江润州支行拟减持合计不超1%股份 | | | 经纬恒海 | 监事崔文革拟减持不超60万股 | | | 新相微 | 科宏芯拟减持不超1%股份 | | | 武进不锈 | 3名高管拟合计减持不超62.34万股公司股份 | | | 美心晟 | 股东WI Harper Fund VII拟减持不超1%股份 | | | 中润光 ...

【导读】有棵树实际控制人肖四清等被证监会立案 上述行为违反了深交所《创业板股票上市规则》相关规定。 值得注意的是，有棵树9月22日公告，公司董事会近日收到副总经理兼董事会秘书章军的书面《辞职报 告》，章军因个人原因决定辞去公司副总经理兼董事会秘书职务，辞任后章军将不在公司担任其他任何 职务。章军的原定任期至第六届董事会任期届满即2025年10月30日止。 9月29日，有棵树股价以6.93元/股收盘，最新市值为64.4亿元。 （文章来源：中国基金报） 截至2025年6月30日，王维、肖四清、深圳市天行云供应链有限公司分别直接持有有棵树股份9.89%、 3.28%、2.76%，分别为有棵树的单一第一大股东、第四大股东、第六大股东。同时，肖四清还是有棵 树的实际控制人。 7月25日，有棵树收到深交所的监管函，监管函称：王维、深圳市天行云供应链有限公司、长沙云蜀信 息科技有限公司、湖南好旺企业管理合伙企业（有限合伙）（以下合称产业投资人）合计持有有棵树 18%的股份。 董秘辞职仅一周，有棵树实际控制人肖四清等即被证监会立案。 2025年7月2日，产业投资人向有棵树发出通知函，拟自行召开股东会审议董事会改组议案，并要求 ...

智通财经APP讯，有棵树(300209.SZ)公告，公司股东肖四清、王维与深圳市天行云供应链有限公司近日 收到中国证券监督管理委员会("中国证监会")下发的《立案告知书》。因涉嫌未按规定披露其他重大信 息等违法违规，中国证监会决定对肖四清、王维与深圳市天行云供应链有限公司立案。 ...

格隆汇9月29日丨有棵树(300209.SZ)公布，公司股东肖四清先生、王维先生与深圳市天行云供应链有限 公司近日收到中国证券监督管理委员会（简称"中国证监会"）下发的《立案告知书》。因涉嫌未按规定 披露其他重大信息等违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律 法规，中国证监会决定对肖四清先生、王维先生与深圳市天行云供应链有限公司立案。股东肖四清先 生、王维先生与深圳市天行云供应链有限公司将积极配合中国证监会立案调查工作，并严格按照相关法 律法规的规定和监管要求及时履行信息披露义务。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

有棵树表示，股东肖四清、王维与深圳市天行云供应链有限公司将配合证监会立案调查工作，并按照相 关法律法规的规定和监管要求及时履行信息披露义务。 北京商报讯(记者董亮实习记者李佳雪)9月29日晚间，有棵树（300209）披露公告称，公司股东肖四 清、王维与深圳市天行云供应链有限公司近日收到证监会下发的《立案告知书》。因涉嫌未按规定披露 其他重大信息等违法违规，根据法律法规，证监会决定对肖四清、王维与深圳市天行云供应链有限公司 立案。 ...

人民财讯9月29日电，有棵树（300209）9月29日公告，公司股东肖四清、王维与深圳市天行云供应链有 限公司近日收到中国证监会下发的《立案告知书》。因涉嫌未按规定披露其他重大信息等违法违规，根 据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对肖四清、 王维与深圳市天行云供应链有限公司立案。 ...

有棵树(300209.SZ)公告称，公司股东肖四清、王维及深圳市天行云供应链有限公司近日收到中国证监 会下发的《立案告知书》，因涉嫌未按规定披露其他重大信息等违法违规，中国证监会决定对上述主体 立案。公司将积极配合调查工作，并及时履行信息披露义务。 ...

证券代码：300209 证券简称：有棵树 公告编号：2025-069 有棵树科技股份有限公司 关于公司股东收到中国证券监督管理委员会《立案告知书》 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 有棵树科技股份有限公司（以下简称"公司"）股东肖四清先生、王维先生 与深圳市天行云供应链有限公司近日收到中国证券监督管理委员会（以下简称 "中国证监会"）下发的《立案告知书》（编号：证监立案字0132025021号、证 监立案字0132025022号、证监立案字0132025023号）。因涉嫌未按规定披露其他 重大信息等违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处 罚法》等法律法规，中国证监会决定对肖四清先生、王维先生与深圳市天行云供 应链有限公司立案。 股东肖四清先生、王维先生与深圳市天行云供应链有限公司将积极配合中国 证监会立案调查工作，并严格按照相关法律法规的规定和监管要求及时履行信息 披露义务。 公司指定信息披露媒体为《证券时报》《中国证券报》及巨潮资讯网 （www.cninfo.com.cn），公司相关信息均以上述指定媒体披露的公告为 ...